Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
Fabry disease is an inherited lysosomal storage disease caused by deficiency of alpha-galactosidase A. Enzyme replacement therapy for this multisystem progressive disease has been available only since 2001. We here report the first known successful pregnancy of a female patient receiving such therapy.
Wendt
S
S
Children's University Hospital Mainz, Mainz, Germany.
Whybra
C
C
Kampmann
C
C
Teichmann
E
E
Beck
M
M
D000328:Adult; D057487:Enzyme Therapy; D000795:Fabry Disease / Q000150:complications / Q000628:therapy*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007527:Isoenzymes / Q000627:therapeutic use; D016464:Lysosomal Storage Diseases / Q000150:complications / Q000628:therapy; D008297:Male; D011247:Pregnancy; D011248:Pregnancy Complications; D011256:Pregnancy Outcome; D011994:Recombinant Proteins; D016896:Treatment Outcome; D000519:alpha-Galactosidase / Q000378:metabolism / Q000627:therapeutic use*
D007527:Isoenzymes; D011994:Recombinant Proteins; C000627036:agalsidase alfa; D000519:alpha-Galactosidase